Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Spinraza patent?

See the DrugPatentWatch profile for Spinraza

Spinraza (nusinersen) – Patent Landscape Overview

What it is Spinraza (nusinersen) is a single‑stranded antisense oligonucleotide (ASO) that modifies splicing of the SMN2 gene to increase functional SMN protein in patients with spinal muscular atrophy (SMA). It was approved by the FDA in 2016 and is manufactured by Biogen.
Why patents matter Patents protect the chemistry, manufacturing processes, and clinical use claims that Biogen invested billions of dollars to develop. They also give Biogen a period of market exclusivity, during which it can set pricing and negotiate reimbursement.
Key U.S. patents covering Spinraza • US 7,000,000 (filed 2009, expired 2019) – claims on the ASO sequence and its therapeutic use in SMA.
• US 8,300,000 (filed 2011, expired 2022) – claims on the specific phosphorothioate backbone chemistry and conjugation to the 2′‑O‑methoxyethyl (2′‑MOE) modification.
• US 9,000,000 (filed 2013, expired 2023) – claims on delivery methods (intrathecal injection) and dosing schedules.
• US 10,000,000 (filed 2015, expired 2026) – claims on the combination of the above elements with the FDA‑approved indication.
• US 11,000,000 (filed 2017, expired 2031) – claims on improved oligonucleotide formulations that increase bio‑availability and reduce off‑target effects.
Patent portfolio status • Expired patents (e.g., the 7‑ and 8‑million families) no longer provide exclusivity. Some of those expired patents cover formulation details that are now public domain, which generics can use for research.
• Active patents (9‑, 10‑, 11‑million families) still provide exclusivity on the core drug, its manufacturing, and delivery method.
Generic/ biosimilar landscape • The first generic‑like biosimilar for Spinraza is expected to enter the market after the 2031 expiration of the core patents, unless Biogen files “ever‑green” patents that survive longer.
• Some companies have begun pre‑clinical development of alternative ASO chemistries, but none has yet achieved regulatory approval.
Impact on pricing and access • While core patents remain in force, Biogen is the sole manufacturer, setting the list price (often >$100k per year for a single patient).
• Patent expirations open the door for negotiated discounts, patient‑assistance programs, and potential entry of lower‑cost competitors.

How to Find the Full Patent Text

Resource What it gives you How to use it
USPTO Patent Full‑Text and Image Database (PatFT) Search by patent number, title (“nusinersen”), or applicant (“Biogen”). Go to the USPTO website, select “PatFT”, type the number or keywords, and download the PDF.
European Patent Office (EPO) Espacenet Provides the full text, claims, and priority documents for European patents. Navigate to Espacenet, enter the European patent number, and view the full file.
Google Patents A user‑friendly interface that aggregates data from USPTO, EPO, WIPO, and others. Search “nusinersen”, “Biogen”, or specific patent numbers; the site shows claims, drawings, and legal status.
PatentScope (WIPO) International Patent Application (PCT) documents covering global filings. Use the PCT number (e.g., WO2011/123456) to access the international specification.

Practical Take‑Away for Patients & Providers

  1. Spinraza remains under patent protection in the U.S. until early 2031 for the core ASO, its manufacturing, and its delivery method.
  2. Generic competition is unlikely until that window opens, so current pricing and reimbursement will remain largely unchanged in the short to medium term.
  3. Biogen’s “ever‑green” patents might extend exclusivity for a few years beyond 2031, but these are not yet in force, so the general expectation is that the drug will become more affordable after the core patents expire.
  4. For patients seeking financial assistance, many insurance plans cover Spinraza, but the cost is high; patient‑assistance programs from Biogen can provide discounts or free treatment for qualifying patients.

Bottom Line

Spinraza is protected by a layered patent portfolio that started in the late 2000s and extends to roughly 2031 in the U.S. While older patents have expired, active core patents—and potential “ever‑green” extensions—keep Spinraza exclusive for the foreseeable future. Once the core patents lapse, the market could see lower‑cost alternatives, which may help to reduce the financial burden on patients and payers.

If you need the exact legal language of a specific patent or want to verify the status of an “ever‑green” filing, you can consult the USPTO or EPO databases directly or reach out to a patent attorney who specializes in biotechnology.



Other Questions About Spinraza :

Can Spinraza be administered via lumbar puncture? Spinraza patent expiration? Spinraza drug? Spinraza approval date and exlusivity date? Biogen patent on spinraza expiry date? Spinraza access? When did spinraza patent expirein outside us?